Rifamycin B biosynthesis by Amycolatopsis mediterranei S699 involves a number of unusual modification reactions in the formation of the unique polyketide backbone and decoration of the molecule. A number of genes believed to be involved in the tailoring of rifamycin B were investigated and the results confirmed that the formation of the naphthalene ring moiety of rifamycin takes place during the polyketide chain extension and is catalysed by Rif-Orf19, a 3-(3-hydroxyphenyl)propionate hydroxylase-like protein. The cytochrome P450-dependent monooxygenase encoded by rif-orf5 is required for the conversion of the D12, 29 olefinic bond in the polyketide backbone of rifamycin W into the ketal moiety of rifamycin B. Furthermore, Rif-Orf3 may be involved in the regulation of rifamycin B production, as its knock-out mutant produced about 40 % more rifamycin B than the wild-type. The work also revealed that many of the genes located in the cluster are not involved in rifamycin biosynthesis, but might be evolutionary remnants carried over from an ancestral lineage.
INTRODUCTION
Rifamycin continues to play a significant role in clinical medicine. Synthetically modified derivatives, such as rifampicin, rifabutin and rifapentine, remain the principal chemotherapeutic agents used for combating tuberculosis, leprosy and AIDS-related mycobacterial infections (Maggi et al., 1966; Ramos-e-Silva & Rebello, 2001; Sepkowitz et al., 1995) . The potent antibacterial activity of this class of antibiotics is due to their specific inhibition of bacterial DNA-dependent RNA polymerases (Campbell et al., 2001; Wehrli & Staehelin, 1969) . At the same time, they have relatively low if any activity against eukaryotic RNA polymerases. Due to their high selectivity for their molecular target, the rifamycins have become a safe and effective medication. Unfortunately, as with many other antibiotics, the incidence of resistance of Mycobacterium tuberculosis, the causative agent of tuberculosis, to rifamycins is continuing to increase over time, due largely to mutational alterations of the target molecule, the b subunit of RNA polymerase (Kirschbaum & Gotte, 1993; Suzuki et al., 1995) . This high-level resistance has contributed to the recent reemergence of tuberculosis as a major health problem and the consequent increase in the death toll among world populations (Dye et al., 2002) . Therefore, new drug discovery and continued development of the existing drugs to combat tuberculosis is indispensable.
Despite the preparation of a large number of rifamycin derivatives by semi-synthetic approaches, the structural modifications have been limited primarily to one region of the molecule, the C-3 or C-4 positions of the aromatic core unit (Cricchio et al., 1974 (Cricchio et al., , 1975 Maggi et al., 1965; Wehrli et al., 1987) . Alterations at other locations are difficult to accomplish chemically due to the complexity of the molecule, and require the implementation of alternative methodology, including combinatorial biosynthesis or mutasynthesis, to achieve additional structural diversity.
The biosynthesis of rifamycin has been studied extensively by both classical feeding and mutagenesis experiments, as well as by contemporary genetic and biochemical approaches (August et al., 1998; Floss & Yu, 2005; Ghisalba & Nuesch, 1981; Schupp et al., 1998) . The polyketide framework of rifamycin B is assembled from 3Present address: Department of Chemical and Biological Engineering, Gyeongsang National University, Jinju 660-701, Korea.
Abbreviations: ACP, acyl carrier protein; AHBA, 3-amino-5-hydroxybenzoic acid; DMDARS, 27-O-demethyl-25-O-desacetylrifamycin S; DMDARSV, 27-O-demethyl-25-O-desacetylrifamycin SV; DMRSV, 27-O-demethylrifamycin SV; ESI-MS, electrospray ionization mass spectrometry; hyg 3-amino-5-hydroxybenzoic acid (AHBA), which arises from the aminoshikimate pathway (Kim et al., 1998; Yu et al., 2001) , two molecules of acetate and eight molecules of propionate. Synthesis of the core structure of rifamycin is catalysed by five multifunctional proteins (RifA-RifE) and an amide synthase (RifF) (Fig. 1A) (August et al., 1998; Schupp et al., 1998) . A loading module that contains domains homologous to adenylation and thiolation (A-T) domains of non-ribosomal peptide synthetases (NRPS) is located on RifA and recognizes AHBA as the starter unit (Admiraal et al., 2001 (Admiraal et al., , 2002 . This is processively extended by malonyl-CoA and methylmalonyl-CoA via ten individual modules of a type I polyketide synthase (PKS) to give rise to the polyketide backbone of rifamycin. The amide synthase (RifF) catalyses the release of this linear product from the PKS complex and its cyclization via intramolecular amide formation. Inactivation of RifF results in the premature release of a series of polyketides of different chain length from the enzyme complex (Stratmann et al., 1999; Yu et al., 1999) , and reveals that the formation of the naphthalene ring of rifamycin occurs during the chain extension. However, further studies are required to determine the mechanism and genes responsible for the construction of the naphthalene core motif.
Proansamycin X has been proposed to be the earliest (A) (B) (Fig. 1B) (August et al., 1998) . Further tailoring reactions of proansamycin X would first give rise to rifamycin W, which is known as an early central intermediate in biosynthesis and the precursor of a variety of other rifamycin derivatives (White et al., 1974) . The basic skeleton of rifamycin W is essentially different from that of rifamycin B. The former compound has an olefinic moiety in its backbone structure, while the latter has a ketal structure. Thus, bioconversion from rifamycin W to rifamycin B must involve a major polyketide backbone rearrangement, which includes an oxidative cleavage of the olefin moiety, an oxidative removal of C-34a and a reduction of the quinone. These are followed by the attachment of side chain moieties to C-4, C-25 and C-27 to complete the final decoration of the molecule. A recent study provides evidence that the acetylation of C-25 takes place prior to the methylation of C-27 (Xu et al., 2003) . Rif-Orf20, a homologue of the M. tuberculosis PapA5 protein, has been found to be responsible for the acetylation of 27-O-demethyl-25-O-desacetylrifamycin SV (DMDARSV) to give 27-Odemethylrifamycin SV (DMRSV) (Xiong et al., 2005) , whereas Rif-Orf14, a methyltransferase, is responsible for the methylation of DMRSV to rifamycin SV (Xu et al., 2003) . Although the bioconversion from DMDARSV to rifamycin SV, and to some extent from rifamycin SV to rifamycin B, has been investigated, little is known about the details of other tailoring reactions and their corresponding enzymes, in particular, those from proansamycin X to DMDARSV. To remedy this, we have constructed a number of mutants of Amycolatopsis mediterranei S699 in which one or more genes located in the regulatory and post-PKS modification region are inactivated, and the mutants were analysed for their ability to produce secondary metabolites. The results of the present study provide evidence that implicates rif-orf19 and rif-orf5 in the formation of the naphthalene moiety and the unusual polyketide backbone rearrangement in rifamycin B biosynthesis, respectively.
METHODS
Micro-organisms, culture conditions and vectors. The rifamycin B-producing strain, A. mediterranei S699, was obtained from Professor Giancarlo Lancini at the former Lepetit Laboratories, Geranzano, Italy. For sporulation it was grown at 30 uC on agar plates containing YMG (yeast extract, malt extract and glucose) medium (Kim et al., 1998) . YMG liquid medium was used for both seed and production cultures. Escherichia coli XL-1 Blue (Stratagene) was used as host for subcloning. pBluescript II SK(2) (Stratagene) was used as vector for subcloning and gene inactivation. A. mediterranei transformants were selected with 70 mg hygromycin B ml 21 in both solid and liquid media. E. coli strains were grown in LB media supplemented with carbenicillin (100 mg ml 21 ) and/or hygromycin B (70 mg ml 21 ) for selection of plasmids. Plasmids carrying disrupted or truncated genes used in the inactivation experiments were constructed as follows.
pTM0031AB. A 5?6 kb FspI/SpeI fragment containing the region from part of orf16 to part of the rpoB gene, the very end of the rifamycin B biosynthetic gene cluster, and a 6?8 kb FspI/FspI fragment containing the region from part of rifN to part of orf5, were individually cloned from the cosmid clone pFKN108 into the pBluescript II SK(2) vector at SmaI/SpeI and EcoRV multiple cloning sites, respectively, providing plasmids pTM0031A and pTM0031B (Fig. 2) . Combination of the blunt ends FspI with SmaI and FspI with EcoRV generated new recleavable sites AciI and SfaNI on pTM0031A and pTM0031B, respectively. Plasmid pTM0031B was then digested with KpnI and the resulting 4?5 kb KpnI/KpnI fragment was inserted into KpnI-digested pTM0031A to give pTM0031AB.
Disruption of rif-orf3. A 7?8 kb EcoRV/BstXI fragment of pFKN108 ( Fig. 3 ) was subcloned into pBluescript II SK(2) at the EcoRV/BstXI sites. The resulting plasmid pTM4502 was then digested with KpnI to give a 8?2 kb, a 2?3 kb and a 0?2 kb fragment. The 8?2 kb and 2?3 kb fragments were recovered from agarose gel. The 8?2 kb fragment was dephosphorylated by alkaline phosphatase and then religated to the 2?3 kb fragment with T4 DNA ligase (NEB) so as to delete a 0?2 kb fragment within rif-orf3 and give pTM45023.
Disruption of rif-orf4. pTM4502 was partially digested with NotI (0?01 unit ml 21 ), and the resulting complementary single-stranded sticky ends were filled by treatment with DNA polymerase I, Klenow fragment (Gibco) and 1 mmol of each deoxynucleoside triphosphate (Gibco), to generate blunt ends at the cut site. The formed bluntend linear plasmid was religated with T4 DNA ligase such that the translated reading frame was shifted to give pTM45024.
Disruption of rif-orf5. pTM4502 was digested with ApaI and then incubated with Klenow enzyme in the same way as rif-orf4 to give pTM45025.
Disruption of rif-orf9. A 7?1 kb BsiWI/BsiWI DNA fragment from pFKN108 ( Fig. 3) containing part of rif-orf9, rif-orfs 10, 11, 17, 18 and part of rif-orf19 was blunt-ended with Klenow enzyme and subcloned into pBluescript II SK(2) at the EcoRV site to give pTM0035. Deletion of a 3?3 kb SphI/SphI fragment of pTM0035 provided pTM0035S, which was then digested with SmaI to give a 3?1 kb and a 3?7 kb fragment. The 3?7 kb fragment, containing the vector and part of rif-orf9, was recovered from agarose gel and religated to give pTM0035S9.
Disruption of rif-orf10. pTM0035S was digested with SacI/NcoI to give a 6?4 kb and a 0?4 kb fragment. The 0?4 kb fragment (part of orf10) was recovered from the agarose gel, blunt-ended using Klenow enzyme and inserted into pBluescript II SK(2) at the EcoRV site to give pTM0035S10.
Disruption of rif-orfs 11 and 18. pTM0035 was partially digested with MluI (0?1 unit ml 21 ) to produce linear DNA with a cutting site within orf11, or within orf18. The cut plasmid DNA was bluntended using Klenow enzyme and dNTP mixture, and then religated. The obtained plasmids had either orf11 or orf18 disrupted and could be discriminated by digesting the plasmids with MluI and XbaI. The one with a disrupted orf11 was designated pTM00351, and that with a disrupted orf18, pTM00358.
Disruption of rif-orf13. A 3?4 kb StuI/XmnI DNA fragment from pFKN108 ( Fig. 3) containing part of rif-orf20, rif-orfs 12, 13, 14 and part of rif-orf15 was cloned into pBluescript II SK(2) at the EcoRV Fig. 2 . Construction of plasmid pTM0031ABH. All circular plasmids were derived from pBluescript II SK(") containing the ampicillin resistance gene (bla). Fig. 3 . Restriction map of part of the rifamycin biosynthetic gene cluster on pFKN108. Solid bars indicate DNA fragments cloned into pBluescript II SK(") or pAMR1 vectors. Ap, ApaI; Bg, BglII; BH, BamHI; BW, BsiWI; BX, BstXI; EI, EcoRI; EV, EcoRV; Kp, KpnI; Mu, MluI; Nc, NcoI; Nt, NotI; Sm, SmaI; Sa, SacI; Sc, ScaI; Sp, SphI; St, StuI; Xm, XmnI.
site to give pTM1304. The plasmid was partially digested with NcoI (1 unit ml 21 ) and the cut plasmid DNA was blunt-ended using Klenow enzyme and dNTP mixture, and then religated with T4 DNA ligase. The obtained plasmids had either orf12 or orf13 disrupted and could be discriminated by digesting the plasmids with NcoI/EcoNI or NcoI/XbaI. The desired construct was designated pTM1304K.
Disruption of rif-orf16. A 3?6 kb NotI/ApaI DNA fragment from pFKN108 ( Fig. 3) , containing part of rif-orf15, rif-orf16 and rifJ, was cloned into pBluescript II SK(2) at the NotI/ApaI sites to give pTM1601. The plasmid was digested with BamHI and the cut plasmid DNA was blunt-ended using Klenow enzyme and dNTP mixture, and then religated to give pTM1601K.
Disruption of rif-orf19. pTM1303 (Xu et al., 2003;  Table 1 ) was digested with HindIII, StuI and EcoRI to produce a 3?2 kb and a 5?9 kb fragment. The 3?2 kb fragment containing rif-orf19 was inserted into pBluescript II SK(2) at the HindIII/StuI site to give pTM1901. The 5?9 kb fragment containing rif-orf14 was inserted into pBluescript II SK(2) at the StuI/EcoRI site to give pTM1401 (Xu et al., 2003) . pTM1901 was then digested with BglII and incubated with Klenow enzyme as previously described to give pTM1901B.
Introduction of the hygromycin B resistance gene (hyg R
). All constructed plasmids were marked for selection by hyg R by cloning a 1?7 kb KpnI/KpnI fragment from plasmid pIJ5607 (Yu et al., 2001) into the KpnI site of pTM0031AB, pTM45023, pTM45024, pTM45025, pTM0035S9, pTM0035S10, pTM00351, pTM00358, pTM1304K, pTM1601K and pTM1901B, resulting in pTM0031ABH, pTM45023H, pTM45024H, pTM45025H, pTM0035S9H, pTM0035S10H, pTM00351H, pTM00358H, pTM1304KH, pTM1601KH and pTM1901BH, respectively.
Construction of pTM1312. pTM1303 was digested with MluI to produce a 5?7 kb fragment containing part of rif-orf14, rif-orfs 13, 12, 20, 19, and part of rif-orf18. The fragment was inserted into pAMR1 at the MluI site to give pTM1312.
Electrotransformation of the plasmid DNAs. All plasmid DNAs were methylated with A. mediterranei S699 cell extract and S-adenosyl-L-methionine before use. Transformation of heatdenatured methylated plasmid DNAs into A. mediterranei S699 was carried out by electroporation at 12?5 kV cm 21 , and the transformants were immediately transferred to a 500 ml Erlenmeyer flask containing 50 ml YMG medium and incubated at 200 r.p.m. and 28 uC for 8-24 h. Single crossover mutants were selected by plating out the cells onto YMG plates containing hygromycin B, which were incubated at 30 uC for 7-14 days. The genotypes of mutant candidates were confirmed by Southern hybridization. Double crossover mutants were selected after three rounds of cultivation of a single crossover mutant in YMG liquid medium by replica plating on YMG agar plates with and without hygromycin B. Colonies that lost the antibiotic resistance were selected and genotypically verified by Southern hybridization as either mutants or revertants. The expected mutant strains were used for further analysis.
Isolation and structure elucidation of rifamycin intermediates. Spores of the mutant strain were initially grown in YMG medium for 3 days at 28 uC and 200 r.p.m. This seed culture was used to inoculate (10 %, v/v) twenty 500 ml Erlenmeyer flasks containing 50 ml of YMG medium. After incubation for 10 days under the same conditions, the cultures were centrifuged, the pooled supernatants acidified to pH 3 with 1 M HCl, and the metabolites extracted with 36100 ml ethyl acetate. (Nakata et al., 1990) .
Treatment of A. mediterranei S699 with ancymidol. Ancymidol (12 mg) was added in two portions to cultures of wild-type strain S699 at 48 and 96 h after inoculation and the products were harvested after 7-10 days' cultivation. Extraction, purification and structure elucidation of the products were carried out according to the procedures described above.
RESULTS

Delineation of the rifamycin post-PKS modification genes
The rifamycin biosynthetic gene cluster is organized into three regions: the PKS genes, the AHBA biosynthetic genes, and the post-PKS modification genes (August et al., 1998) . To determine the extent of the involvement of genes located in the proposed post-PKS modification region of the rif cluster, we generated a mutant strain of A. mediterranei S699, in which a 21 kb KpnI/KpnI fragment downstream of the AHBA biosynthetic genes is deleted from the chromosome. The construction was initiated by the subcloning of two DNA fragments located upstream and downstream of the deleted region from the cosmid clone pFKN108 (August et al., 1998) into the pBluescript II SK(2) vector, providing plasmids pTM0031B and pTM0031A, respectively (Fig. 2) . Plasmid pTM0031B was then digested with KpnI and the resulting 4?5 kb fragment was inserted into KpnI-digested pTM0031A, replacing the 0?9 kb KpnI/KpnI fragment of pTM0031A, to give pTM0031AB, which harbours the hybrid 9?2 kb DNA fragment (Fig. 2) . The constructed plasmid pTM0031AB was marked for selection by hyg R (Yu et al., 2001) , which was obtained from plasmid pIJ5607, and the product was transformed into A. mediterranei S699. Double homologous recombination within the 9?2 kb DNA fragment gave rise to a number of mutants and revertants (genotypically identical to the wild-type). As expected, the mutant strain (MT0031ABH) lacked the 21 kb DNA fragment as confirmed by Southern hybridization (data not shown). The deleted region was located downstream of genes encoding a putative regulator (rifO), an efflux protein (rifP) and a transcriptional repressor (rifQ), and upstream of the aminodehydroquinate dehydratase gene (rifJ), which is known to be involved in the biosynthesis of (Yu et al., 2001) . The mutant strain appeared to be morphologically different from the wildtype, with no apparent rifamycin production on the YMG agar plates. Analysis of the products by HPLC and ESI-MS revealed that the mutant (MT0031ABH) was unable to produce rifamycin B or to produce proansamycin X as one would have expected for mutants lacking the entire set of tailoring enzymes. Instead, the mutant strain produced the tetraketide products SY4b and desacetyl-SY4b (the cyclic forms of P8/1-OG, Fig. 4B ), which have previously been shown to be premature release products when the amide synthase (RifF) is inactivated (Stratmann et al., 1999; Yu et al., 1999) . Negative-ion ESI-MS tandem analysis of desacetyl-SY4b gave fragment ions at m/z 246, 228, 190, 172, 153, 136 , which are consistent with the expected fragmentation patterns for desacetyl-SY4b (Fig. 4C) . The results suggested that the gene(s) responsible for naphthalene ring formation might be located in the deleted region.
Inactivation of the P450-dependent monooxygenases (Rif-Orfs 4, 5, 13 and 16)
There are four genes in the regulatory and post-PKS modification region that encode proteins with homology to the cytochrome P450 family. rif-orf4 encodes a protein homologous to the putative cytochrome P450 oxidoreductases from several Streptomyces species (Trower et al., 1992) . riforfs 5 and 13 encode proteins similar to cytochrome P450 EryF involved in erythromycin biosynthesis (Weber et al., 1991) , and rif-orf16 encodes a protein that shares homology with cytochrome P450 SubC from Streptomyces griseolus (Omer et al., 1990) . To evaluate the roles of these genes in rifamycin B biosynthesis, all four cytochrome P450 genes were individually inactivated and the mutant phenotypes analysed. For rif-orf16 inactivation, a 3?6 kb NotI/ApaI DNA fragment consisting of part of rif-orf15, rif-orf16 and rifJ (Fig. 3 ) was cloned into pBluescript II SK(2) and the targeted gene was disrupted by Klenow fill-in frameshift at a BamHI site to give plasmid pTM1601K, which was then marked with hyg R to give pTM1601KH. As for the rif-orf13 mutation, a 3?4 kb StuI/XmnI fragment of pFKN108 containing rif-orfs 12, 13, 14 and part of rif-orf15 was cloned into the EcoRV site of pBluescript II SK(2), and inactivation of rif-orf13 was achieved by Klenow fill-in frameshift at an NcoI site followed by hyg R insertion to give plasmid pTM1304KH. Inactivation of rif-orfs 4 and 5 was also implemented by Klenow fill-in frameshift, which was done on pTM4502, a pBluescript II SK(2) derivative containing the 7?8 kb EcoRV/BstXI fragment (the region from part of rifP to part of orf7, including the target genes orf4 and orf5) of pFKN108 (Fig. 3) . The frameshift was introduced at NotI and ApaI sites of rif-orfs 4 and 5, respectively, followed by introduction of hyg R . All four constructed plasmids were individually transformed into A. mediterranei S699 for homologous recombination. The single and double crossover mutants were screened by Southern hybridization, cultured in YMG liquid medium for 7 days and the secondary metabolites analysed by HPLC and ESI-MS. The results indicated that inactivation of rif-orf4 and riforf13 did not have any effect on the production of rifamycin B, while mutants of rif-orf16 produced a mixture of rifamycin SV and rifamycin B. Inactivation of rif-orf5, however, inhibited rifamycin B production and caused the accumulation of rifamycin W, an analogue previously isolated from a mutant strain of A. mediterranei strain AE/1 obtained by mutagenesis of spores with nitroguanidine (White et al., 1974) . Rifamycin W production was confirmed by mass spectrometry and 1 H-NMR analysis. Thus we conclude that rif-orf5 is critical for the conversion of rifamycin W to DMDARSV during rifamycin B biosynthesis. However, detailed biochemical studies of the enzyme have not been achieved, as attempts to produce recombinant Rif-Orf5 in E. coli have so far been unsuccessful.
Inhibition of cytochrome P450 monooxygenases by ancymidol
To confirm the involvement of a cytochrome P450 monooxygenase in the conversion of rifamycin W, cultures of wild-type A. mediterranei S699 were treated with ancymidol, an inhibitor of cytochrome P450 monooxygenases (Ralston et al., 2001) , and analysed for compound production. No apparent cell growth inhibition was detected in cultures with ancymidol, relative to those without ancymidol. However, cultures in the presence of ancymidol produced a dark brown colour, which turned to bright yellow when the pH of the culture was adjusted to 2?5 with 0?1 M H 2 SO 4 , whereas those without ancymidol have a light brown colour, indicating a normal production of rifamycin B. TLC, HPLC and ESI-MS analyses of the products revealed that in the presence of ancymidol the bacteria accumulated rifamycin W, supporting the role of a cytochrome P450, presumably Rif-Orf5, in the conversion of rifamycin W to DMDARSV.
Inactivation of rif-orf3
Based on results of the present study and others (Stratmann et al., 1999; Yu et al., 1999) , it was clear that the core naphthalene ring moiety of rifamycin is constructed during the polyketide chain extension process. However, the fact that the reaction may require a catalytic enzyme, whose gene is located in the post-PKS modification region and functions in trans with the PKS, is rather unusual. This notion has led us to a closer inspection of a functionally unknown gene (rif-orf3) that is located in the cluster directly upstream of the cytochrome P450-dependent monooxygenase genes rif-orfs 4 and 5. This gene originally showed no similarity to any known proteins in the database (but recently has been found to share high homology with a number of hypothetical proteins predicted from genome sequences; see Discussion). In silico analysis of the amino acid sequence revealed the presence in the protein of a putative flavinnucleotide-binding region (Marchler-Bauer et al., 2003) , which might be involved in a phenolic hydroxylation reaction, making this gene an intriguing candidate for gene inactivation experiments. Therefore, disruption of rif-orf3 was implemented by an internal deletion of a 0?2 kb KpnI/ KpnI fragment from the gene, and the mutant phenotype was analysed by HPLC and ESI-MS. The mutant gave an identical phenotypic pattern to that of the wild-type strain, but produced about 40 % more rifamycin B than the wildtype, suggesting that rif-orf3 is involved in the regulation of rifamycin B production rather than in the formation of the naphthalene ring.
Involvement of Rif-Orf19 in naphthalene ring formation
As neither the P450 monooxygenases nor rif-orf3 are directly involved in naphthalene ring formation, we then focused on rif-orf19, which encodes a protein homologous to 3-(3-hydroxyphenyl)propionate hydroxylases, a group of flavoproteins that catalyse the hydroxylation of phenol structures. This includes the 3-(3-hydroxyphenyl)propionic acid hydroxylases (HppA or MhpA) from Rhodococcus globerulus (32 % identity, 46 % similarity) (Barnes et al., 1997) , E. coli strain K-12 (35 % identity, 51 % similarity) (Blattner et al., 1997) and Comamonas testosteroni TA441 (37 % identity, 50 % similarity) (Arai et al., 1999) . Genes similar to rif-orf19 have also been reported to be involved in a number of secondary metabolite biosyntheses, such as in the biosyntheses of the antitumour antibiotic geldanamycin (gdmM; 46 % identity and 59 % similarity at the protein level) (Rascher et al., 2003) and of the aromatic myxobacterial electron transport inhibitor stigmatellin (stiL; 27 % identity, 41 % similarity at the protein level) (Gaitatzis et al., 2002) . In silico analysis of the amino acid sequences revealed that all the proteins within this family contain typical nucleotide-binding motifs for flavoprotein hydroxylases with the amino acid sequences GxGxxG, DGxxSxxR and GDxxH (Fig. 5) (Enroth et al., 1998; Eppink et al., 1997) .
To inactivate rif-orf19, a 3?2 kb HindIII/StuI DNA fragment derived from pTM1303 harbouring part of rif-orf18, rif-orf19, and part of rif-orf20 was subcloned into vector pBluescript II SK(2) followed by introduction of hyg R to give plasmid pTM1901BH. Inactivation of rif-orf19 was achieved by Klenow fill-in frameshift at a BglII site. Introduction of this mutation into the wild-type strain abolishes the ability of the micro-organism to produce rifamycin B, and as expected, the mutant produces desacetyl-SY4b, which is identical to the compound isolated from the 21 kb deletion mutant strain MT0031ABH.
Complementation of rif-orf19
To confirm the direct involvement of rif-orf19 in rifamycin B biosynthesis, a complementation experiment was carried out by introducing the wild-type rif-orf19 gene into the mutant strains using a replicating vector derived from plasmid pULVK2 (Kumar et al., 1994) . Thus, a 5?7 kb MluI/MluI fragment of pTM1303 harbouring the complete operon of rif-orfs 13, 12, 20 and 19 was cloned into pAMR1, a pULVK2 (Kumar et al., 1996) plasmid modified by the laboratory of Professor C. R. Hutchinson at the University of Wisconsin by introducing hyg R and a multiple cloning site (MCS). The resulting plasmid (pTM1312) was electrotransformed into mutant strain MT1901BH and the transformants were selected on YMG plates containing the antibiotic hygromycin. Positive transformants could be easily identified by the diffusion of red-brown colour around the colonies on agar plates, which was further analysed by ESI-MS to show the recovery of rifamycin B production in these transformants. To confirm their genetic make-up, recovery of the plasmids was attempted by 'electroduction' (Tuteja et al., 2000) of the plasmid from the transformants into E. coli using procedures suggested by Lal and co-workers (Tuteja et al., 2000) ; however, no plasmid could be recovered. On the other hand, Southern hybridization of the total cellular DNA using a 1?5 kb BglII/HindIII fragment of pTM1901 containing parts of rif-orf18 and rif-orf19 and a 1?7 kb fragment containing the hyg R gene as probes gave strong signals, albeit in DNA of sizes that were different from those predicted for either the free plasmid or for plasmid that has been accidentally incorporated into the chromosome. This could be due to rearrangement and/or deletion of DNA fragments of pTM1312 in A. mediterranei, as such events have previously been reported for pULVK2 derivatives (Tuteja et al., 2000) . While the restriction patterns could not be readily explained, the strong hybridization signals for both probes indicated the presence of both rif-orf19 and hyg R genes in the cells. No signal could be detected in the Southern hybridization of wild-type and mutant MT1901BH DNA using the hyg R gene as a probe.
Inactivation of rif-orfs 9, 10, 11 and 18
Finally, to determine if any of the following genes -rif-orf9 (putative aminotransferase), rif-orf10 (putative oxidoreductase), rif-orf11 (putative reductase) and rif-orf18 (putative 2,3-dehydratase) -are involved in rifamycin B biosynthesis, they were individually inactivated by either single or double crossover recombination. Mutants generated by these experiments were grown in YMG medium and the products analysed by LC-MS. All mutants produced rifamycin B in amounts comparable to the wild-type, indicating that those gene products are not involved in rifamycin B biosynthesis.
DISCUSSION
The genetic organization of the rifamycin biosynthetic gene cluster comprises a set of PKS modules (rifA-E), an amide synthase (rifF), the AHBA biosynthetic genes, and the regulatory and post-PKS modification genes (August et al., 1998) . The regulatory and post-PKS modification genes span a region of 25 kb directly downstream of the AHBA biosynthesis gene subcluster. rifO, rifP and rifQ have been proposed to be involved in regulation or in a resistance mechanism. rif-orf3, a gene located immediately downstream of rifQ, may also play a regulatory role in rifamycin biosynthesis, as inactivation of the gene resulted in a 40 % increase of rifamycin B production. This functionally unknown gene encodes a protein that shares high homology with the hypothetical protein MAP2411 of Mycobacterium avium subsp. paratuberculosis str. K10 (44 % identity, 58 % similarity) and the hypothetical protein SCO4419 of Streptomyces coelicolor A3(2) (41 % identity, 57 % similarity).
The aminodeoxyhexose genes (rif-orfs 6-10) in the cluster have been proposed to be functionally silent (August et al., 1998) . This notion is based on the fact that no glycosylated rifamycins are found in cultures of A. mediterranei S699. On the other hand, glycosylated rifamycin congeners (tolypomycins) have been isolated from another rifamycin B producer, Streptomyces tolypophorus (Kishi et al., 1969 (Kishi et al., , 1972 . Previous work on these genes revealed that inactivation of rif-orfs 6 and 9, which encode proteins homologous to dNTP-hexose dehydratase (RfbH) of Salmonella enterica and aminotransferase (YokM) of Bacillus subtilis, respectively, results in mutants that produce rifamycin B, indicating that there is no direct involvement of these genes in rifamycin B biosynthesis (August et al., 1998; M. Müller and others, unpublished results) . These findings have been confirmed by the results of our experiments, as individual inactivation of rif-orfs 9, 10, 11, and 18 also does not affect rifamycin B production.
The first cyclization product released from the rif PKS is believed to be proansamycin X, a hypothetical molecule that has never been isolated or identified. It was expected that deletion of the entire set of post-PKS modification genes from the chromosome might give mutants that produce proansamycin X. However, mutant strain MT0031ABH, in which a 21 kb fragment of the post-PKS modification genes has been deleted, did not accumulate proansamycin X, but instead the tetraketides SY4b and desacetyl-SY4b were produced. These compounds have previously been isolated from knock-out mutants of the amide synthase RifF, as a result of premature release of the polyketide chain intermediates from the enzyme, starting from the tetraketide through the undecaketide (Stratmann et al., 1999; Yu et al., 1999) . Structure identification of these intermediates showed that from the pentaketide onwards they contain a naphthalene ring, suggesting that the formation of the naphthalene moiety of rifamycin B takes place during the chain extension of the polyketide, specifically between the tetraketide and the pentaketide stage. Therefore, the production of desacetyl-SY4b by MT0031ABH indicates that a gene(s) responsible for the formation of the naphthalene ring is located in the deleted region. However, attempts to complement the missing genes with a 28?1 kb EcoRV/SpeI fragment, harbouring all genes of the deleted region (Fig. 2) , have not been successful. It has been proposed that the formation of the naphthalene ring would require the introduction of an oxygen into the aromatic ring at the position para to the hydroxyl group of AHBA, followed by quinone formation and cyclization by a Michael addition . The initial reaction might be catalysed by one of the cytochrome P450 monooxygenases (Fig. 6) . However, individual inactivation of rif-orfs 4, 13 and 16 did not significantly affect rifamycin B production. Interestingly, the rif-orf16 mutant produces both rifamycins SV and B, which raises a question whether riforf16 may to some extent be involved in the formation and/or attachment of the glycolate side chain.
Another P450 gene in the cluster, rif-orf5, was shown to be involved in the modification of rifamycin W, a rifamycin analogue that has been proposed to be a progenitor of rifamycin B. White and co-workers experimentally showed that washed mycelium from a rifamycin B-producing strain of A. mediterranei transformed rifamycin W into rifamycin B (White et al., 1974) . As inactivation of rif-orf5 resulted in mutants that produce rifamycin W, we propose that Rif-Orf5 functions in the oxidative cleavage of the C12-C29 double bond of rifamycin W, leading to a rearrangement reaction to form a ketal structure (Fig. 7 ). This is followed by an oxidation of the C-34a alcohol to the carboxylic acid and then a decarboxylation-dehydration to give DMDARS, which may be converted to its redox counterpart, DMDARSV, in the cells (Xu et al., 2003) . Alternative scenarios for the conversion of the C-34a alcohol into DMDARS could involve a retro-aldol cleavagedehydration to release C34a as formaldehyde, or oxidation to the C-34a aldehyde and a retro-Claisen reactiondehydration to liberate C-34a as formic acid. The C-34a alcohol of rifamycin W may be derived from the C-34a methyl group of proansamycin X by one of the P450-dependent monooxygenases. None of the P450 genes located in the post-PKS modification gene cluster seems to be responsible for this reaction. However, another P450 gene, rif0, located immediately upstream of rifA, could be responsible for the reaction. Mutational analysis of this gene by the group of Hutchinson did not give conclusive results (C. R. Hutchinson, personal communication). Alternatively, the P450 enzymes may have relaxed substrate specificity, so that when one of the enzymes is disrupted, its function will be complemented by the others.
Disruption of rif-orf19 ceased production of rifamycin B and caused the accumulation of the tetraketides SY4b and desacetyl-SY4b, implicating rif-orf19 in the formation of the naphthalene ring of rifamycin B. The use of a tailoring enzyme in trans for the formation of the naphthalene ring during polyketide chain extension is unprecedented in polyketide biosynthesis. To date, a number of unusual examples have been reported in PKS systems, in which the acyltransferase domain is located outside the PKS modules and functions in trans with the modular enzymes (Cheng et al., 2003; Piel, 2002) . However, there are no examples of an oxidation reaction that takes place during polyketide chain assembly nor of an oxidation domain located within a modular PKS system. This kind of reaction is more commonly seen in the NRPS systems, in which oxidation domains are usually located within NRPS modules (Du et al., 2000; Weinig et al., 2003) . Nevertheless, based on the present results, it is proposed that Rif-Orf19 functions as a separate enzyme that interacts with the PKS, introducing a hydroxyl group into the acyl carrier protein (ACP)-bound tetraketide. This sets the stage for the further enzymecatalysed or spontaneous cyclization reaction to form the naphthalene ring. Whether a single enzyme or a complex of enzymes is responsible for the entire process remains to be investigated. Failure of this cyclization to take place, as in the rif-orf19 mutant, leads to rejection of the nascent ketide by module 4 of the PKS and release of the tetraketide.
The hydroxylation of ACP-bound tetraketide by an FADdependent hydroxylase also raises an important question regarding the nature of substrate access to the active site. Mechanistically, this class of enzymes requires the cofactors FAD and NADPH, molecular oxygen, and substrate. FAD is in general incapable of catalysing the hydroxyl transfer reaction free in solution; therefore, the catalytic site must be shielded from solvent during the critical step of the hydroxylation reaction. As the substrate is rather bulky and is bound to a large complex protein (PKS), it is less likely that Rif-Orf19 adopts a regular 'open-closed' channel mechanism for substrates and products to enter and leave the active site. The most attractive hypothesis would be that Rif-Orf19 docks onto the PKS and 'engulfs' the tetraketide portion of the ACP-bound substrate, whereas the PKS itself serves as a giant lid to the active site of the hydroxylase. If this is the case, how and when NADPH and molecular oxygen enter the active site would be open questions. Interestingly, alignment analysis of the amino acid residues of Rif-Orf19 with those of related enzymes showed no significant disparity at the sequence levels (Fig. 5) . Instead, all proteins seem to be highly similar, particularly Rif-Orf19 and GdmM (46 % identity, 59 % similarity); the latter is involved in geldamycin biosynthesis (Rascher et al., 2003) . However, there are a number of amino acid residues in RifOrf19 which are different from the conserved residues found in other hydroxylases (indicated by large arrows in Fig. 5 ) and which may play a role in its potentially distinct structural and/or catalytic nature. Detailed biochemical and structural investigations of the protein are critical to address these intriguing questions.
